SQZ Biotechnologies (NYSE: SQZ) is one of 197 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its rivals? We will compare SQZ Biotechnologies to similar businesses based on the strength of its valuation, dividends, risk, profitability, analyst recommendations, institutional ownership and earnings.
This table compares SQZ Biotechnologies and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|SQZ Biotechnologies Competitors||-22,838.38%||-121.87%||-32.56%|
This is a summary of current ratings and target prices for SQZ Biotechnologies and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|SQZ Biotechnologies Competitors||1115||4439||9773||185||2.58|
SQZ Biotechnologies presently has a consensus target price of $38.33, suggesting a potential upside of 183.95%. As a group, “Biological products, except diagnostic” companies have a potential upside of 28.69%. Given SQZ Biotechnologies’ stronger consensus rating and higher possible upside, analysts clearly believe SQZ Biotechnologies is more favorable than its rivals.
Valuation and Earnings
This table compares SQZ Biotechnologies and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|SQZ Biotechnologies||$21.00 million||-$50.52 million||-1.44|
|SQZ Biotechnologies Competitors||$606.09 million||$28.84 million||24.48|
SQZ Biotechnologies’ rivals have higher revenue and earnings than SQZ Biotechnologies. SQZ Biotechnologies is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
39.3% of SQZ Biotechnologies shares are held by institutional investors. Comparatively, 52.9% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 16.8% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
SQZ Biotechnologies Company Profile
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for SQZ Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SQZ Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.